🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Zonghui Ma

Peking University

ORCID: 0000-0002-4265-9319

Also affiliated with Peking University First Hospital, The University of Texas Medical Branch at Galveston

Biochemistry, Genetics and Molecular BiologyMedicineEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors”.

IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors

Molecular Cell(2023)10.1016/j.molcel.2023.11.022
N/A
0DataRank · unranked
28 citations

Hsien‐Tsung Lai, N. Sanjib Banerjee, Zonghui Ma, Juan F. Santana, Shuguang Wei +11 more

RIPTACs: A groundbreaking approach to drug discovery

Drug Discovery Today(2023)10.1016/j.drudis.2023.103774
N/A
0DataRank · unranked
25 citations

Andrew A. Bolinger, Jia Zhou, Zonghui Ma

An updated patent review of BRD4 degraders

Expert Opinion on Therapeutic Patents(2024)10.1080/13543776.2024.2400166
N/A
0DataRank · unranked
24 citations

Cun Zhang, Andrew A. Bolinger, Jia Zhou, Zonghui Ma

BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease

Advances in pharmacology(2024)10.1016/bs.apha.2024.10.008
N/A
0DataRank · unranked
5 citations

Andrew A. Bolinger, Irina V. Pinchuk, Bing Tian, Jia Zhou, Zonghui Ma

RIPTACs for Precision Cancer Therapy: A Novel Modality with the Inspiration of HLD-0915 as the First Candidate in Clinical Trials

Journal of Medicinal Chemistry(2025)10.1021/acs.jmedchem.5c01250
N/A
0DataRank · unranked
11 citations

Cun Zhang, Qiang Shen, Jia Zhou, Zonghui Ma

NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders

Journal of Medicinal Chemistry(2025)10.1021/acs.jmedchem.5c01818
N/A
0DataRank · unranked
56 citations

Jia Zhou, Zonghui Ma